Here, we developed three approaches to measure the SMN transcript level based on real-time RT-PCR, quantitative fluorescent RT-PCR, and semiquantitative RT-PCR gel densitometric assay and validated the best biomarker found in an SMN2-targeting therapeutic experiment in cells derived from SMA patient. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.